Common Contracts
2 similar Equity Distribution Agreement contracts
PROSPECTUS SUPPLEMENTEquity Distribution Agreement • June 17th, 2022
Oncolytics Biotech Inc. (the “Corporation”, “Oncolytics”, “we”, “our” or “us”) may from time to time offer and issue the following securities: (i) common shares in the capital of the Corporation (“Common Shares”); (ii) subscription receipts of the Corporation exchangeable for Common Shares and/or other securities of the Corporation (“Subscription Receipts”); (iii) warrants exercisable to acquire Common Shares and/or other securities of the Corporation (“Warrants”); and (iv) securities comprised of more than one of Common Shares, Subscription Receipts and/or Warrants offered together as a unit (“Units”), or any combination thereof, up to an aggregate offering price of C$150,000,000 (or the equivalent thereof, at the date of issue, in any other currency or currencies, as the case may be) at any time during the 25-month period that this short form base shelf prospectus (including any amendments hereto, the “Prospectus”) remains valid. The Common Shares, Subscription Receipts, Warrants and
US$30,300,000Equity Distribution Agreement • December 4th, 2020
Oncolytics Biotech Inc. (“Oncolytics” or the “Corporation”) has entered into an equity distribution agreement dated June 15, 2020 (the “Equity Distribution Agreement”) with Canaccord Genuity LLC (the “Agent”) relating to our common shares (“Common Shares”) pursuant to which we may offer and sell Common Shares having an aggregate offering price of up to US$40,000,000. This Prospectus Supplement qualifies for distribution an aggregate of up to US$30,300,000 of our Common Shares that may be offered and sold through the Agent, as our agent, under the Equity Distribution Agreement (the “ Offering”). See “Plan of Distribution” beginning on page S-19 of this Prospectus Supplement for more information regarding these arrangements.
